Response to treatment with denosumab in patients with giant cell tumor of bone (GCTB): FDG PET results from two phase 2 trials.
Keith M. Skubitz
Consultant or Advisory Role - Amgen; ARIAD/Merck; Johnson & Johnson; Novartis; Pfizer/Schering-Plough; Systems Medicine
Stock Ownership - Johnson & Johnson
Research Funding - Amgen; ARIAD/Merck; Celgene; Cell Therapeutics; GlaxoSmithKline; Infinity Pharmaceuticals; Schering-Plough; Systems Medicine
Expert Testimony - Plaintiff in class action on role of bisphosphonates in ONJ (U)
Other Remuneration - Amgen
David Morgan Thomas
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Sant P. Chawla
Consultant or Advisory Role - CytRx Corporation; Merck; PharmaMar; Sanofi
Research Funding - CytRx Corporation; Merck; PharmaMar; Sanofi
Arthur P. Staddon
No relevant relationships to disclose
Jacob Engellau
Consultant or Advisory Role - Amgen
Amy Feng
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Bruce A. Bach
Employment or Leadership Position - Amgen
Stock Ownership - Amgen